Loading
C Ray Therapeutics makes radioactive medicines and also manufactures them for other companies. Its own lead treatment, TRC003, carries a radioactive atom to prostate cancer cells and is in an early trial for advanced prostate cancer that no longer responds to hormone treatment.
C Ray Therapeutics (Chengdu) Co., Ltd., at 198 Haida Road, Wenjiang District, Chengdu, China, describes itself as a radiopharmaceutical contract research, development and manufacturing organisation offering process development, preclinical evaluation, IND enabling work, clinical supply and commercial cGMP production, and says it has supported 23 actinium-225 labelled projects. It also develops its own products: TRC003 injection, which the company describes as a therapeutic radiopharmaceutical labelled with actinium-225, is in a phase 1/2 trial in adults with PSMA-positive metastatic castration-resistant prostate cancer (NCT07567521, posted May 2026), and TRDC002 is in a phase 1 diagnostic PET/CT study in PSMA-positive prostate cancer (NCT07236112). Its first registered cancer trial, NCT07236112, was posted on ClinicalTrials.gov in November 2025. The company states that by 2024 it had raised more than USD 187 million in total, and that it formed a Radiopharmaceutical Innovation Alliance with United Imaging, Perceptive, Quarkmed, GoBroad Healthcare and Grand Pharmaceutical Group.
Shares Targeted alpha therapy, PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Targeted alpha therapy, PSMA, Metastatic castration-resistant prostate cancer.
Shares Targeted alpha therapy, PSMA, Prostate cancer.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Radiopharmaceutical GMP and releasing a drug that decays, PSMA, PSMA PET, Metastatic castration-resistant prostate cancer.
Shares PSMA, PSMA PET, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares PSMA, PSMA PET, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/